Understanding Side Effect Differences Through Private Care
Mounjaro vs Wegovy Side Effects: Key Differences for Private Patients
When comparing Mounjaro vs Wegovy side effects through private prescription, both medications share similar gastrointestinal profiles as they target the GLP-1 receptor pathway. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, while Wegovy (semaglutide) targets GLP-1 receptors exclusively, potentially resulting in subtle differences in side effect frequency and severity. The most common side effects for both include nausea, vomiting, diarrhoea, and constipation, typically occurring during dose escalation phases. Through private prescription, patients receive enhanced monitoring and support during these critical adjustment periods, unlike the limited follow-up often experienced through NHS pathways.
Private prescription patients benefit from direct prescriber communication when managing Mounjaro vs Wegovy side effects, enabling rapid dose adjustments or treatment switches if necessary. Both medications carry risks of more serious side effects including pancreatitis, gallbladder problems, and potential thyroid tumours, requiring careful patient selection and ongoing monitoring. EverydayMeds' clinical team, operating under GPhC registration #9012878, provides comprehensive pre-treatment assessments to identify patients at higher risk for severe side effects. This personalised approach ensures patients receive the most appropriate treatment choice based on their individual risk profile and medical history.
Private Prescription Pricing and Value for Mounjaro vs Wegovy Side Effects Management
Understanding the cost implications when comparing Mounjaro vs Wegovy side effects through private prescription helps patients make informed treatment decisions. Wegovy pricing starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). New customers apply discount code FIRST40 at checkout, while returning customers use DOSE25 to access these competitive prices. The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing the first eight weeks of treatment with Reliable Supply continuity.
Mounjaro pricing through private prescription varies by dose and supplier, but the enhanced side effect monitoring included with private care justifies the investment for many patients. Bundle options like the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 ensure treatment continuity during critical dose escalation phases when side effects are most likely to occur. Private prescription eliminates NHS waiting times that can extend 6+ months, during which time patients may experience worsening weight-related health conditions. The Consistency bundles provide ongoing supply security, with Consistency 1mg (×2) at £209.99 and Consistency 2.4mg (×2) at £419.99 for maintenance phases.
Clinical Evidence on Mounjaro vs Wegovy Side Effects from STEP and SURPASS Trials
Clinical evidence comparing Mounjaro vs Wegovy side effects comes from separate trial programmes with different methodologies, making direct comparisons challenging but informative. The STEP trials for Wegovy (Wilding et al., NEJM, 2021) demonstrated that gastrointestinal side effects led to treatment discontinuation in approximately 7% of participants. Common side effects included nausea (44% vs 9% placebo), diarrhoea (30% vs 16% placebo), and vomiting (25% vs 6% placebo), typically peaking during dose escalation phases.
Mounjaro's SURPASS trials showed similar gastrointestinal side effect patterns, with the dual receptor mechanism potentially offering different tolerability profiles in some patients. Both medications demonstrated that most side effects diminish over time as patients adapt to treatment, though individual responses vary significantly. The trials emphasised the importance of proper dose escalation and medical supervision, benefits readily available through private prescription pathways that ensure appropriate clinical oversight.
Understanding How Wegovy and Mounjaro Work Differently
Wegovy functions as a selective GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates blood glucose and gastric emptying. This mechanism promotes satiety by slowing gastric emptying and reducing appetite through direct effects on brain appetite centres. The medication's action on GLP-1 receptors in the pancreas, stomach, and brain creates the coordinated response that supports weight management alongside reduced-calorie diets and increased physical activity. However, this targeted approach can result in specific side effect patterns related to delayed gastric emptying and altered glucose regulation. The once-weekly injection schedule helps maintain consistent therapeutic levels while minimising peak-related side effects. Wegovy's selective mechanism means side effects are primarily related to GLP-1 pathway activation, making them predictable and manageable with proper medical guidance.
Streamlined Private Prescription Process for Both Medications
Accessing either medication through EverydayMeds requires a comprehensive 3-minute clinical assessment covering medical history, current medications, and weight management goals. Our prescribers review each application within 3 working days (24 hours for express service), ensuring appropriate treatment selection based on individual side effect risk profiles. Once approved, both Wegovy and Mounjaro ship via next-day cold-chain delivery, maintaining medication integrity that's crucial for minimising storage-related efficacy issues. The prescription-only medicine status ensures proper medical oversight while eliminating NHS referral delays and waiting lists. Our clinical team provides ongoing support throughout treatment, helping patients navigate side effects and dose adjustments as needed.
Storage and Practical Considerations for Mounjaro vs Wegovy Side Effects
Proper storage significantly impacts medication effectiveness and potential side effects when comparing Mounjaro vs Wegovy options through private prescription. Wegovy offers superior storage flexibility, maintaining stability for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use, delivered through our temperature-controlled supply chain to ensure optimal potency. The FlexTouch pen delivery system used by Wegovy provides consistent dosing accuracy, while proper injection technique training reduces injection site reactions and ensures optimal absorption. Dose escalation schedules differ between treatments, with Wegovy following a structured 4-week progression through 0.25mg, 0.5mg, 1mg, 1.7mg, to maintenance 2.4mg dosing. Following prescribed escalation schedules helps minimise gastrointestinal side effects that commonly occur with rapid dose increases.
Side Effect Management Strategies Through Private Prescription Care
Private prescription patients comparing Mounjaro vs Wegovy side effects benefit from personalised management strategies unavailable through standard NHS pathways. Direct prescriber communication enables rapid intervention when side effects occur, including temporary dose reductions, dietary modifications, or treatment switches if necessary. Our clinical team provides detailed guidance on timing injections with meals, managing nausea through dietary adjustments, and recognising serious side effects requiring immediate medical attention. Advanced planning includes discussing family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, contraindications for both medications.
The enhanced monitoring available through private prescription includes regular check-ins during dose escalation phases when side effects are most prevalent. Patients receive comprehensive information about potential drug interactions, particularly with diabetes medications that may require adjustment to prevent hypoglycaemia. Emergency protocols ensure patients know when to seek immediate medical attention for symptoms suggesting pancreatitis, gallbladder problems, or severe dehydration from persistent vomiting. This proactive approach to side effect management significantly improves treatment tolerability and long-term success rates compared to minimal oversight common in stretched NHS services.
Making Your Treatment Decision with Expert Support
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment best suits your individual side effect risk profile and weight management goals. The decision involves considering your medical history, previous experiences with GLP-1 medications, and lifestyle factors that may influence side effect tolerance. Our clinical assessment process identifies potential contraindications and risk factors, ensuring safe treatment selection. Private prescription eliminates the typical 6+ month NHS specialist referral delays, allowing patients to begin treatment promptly under proper medical supervision. Use discount codes FIRST40 for new customers or DOSE25 for returning customers at checkout to access our competitive pricing. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and take the first step toward medically supervised weight management.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
